A prospective pilot study to assess neoadjuvant chemotherapy for unresectable peritoneal carcinomatosis from colorectal cancer

Colorectal Disease

Volumn 16, Issue 8, 2014, Pages

  Hompes, D ^a   Aalbers, A ^a   Boot, H ^a   van Velthuysen, M L ^a   Vogel, W ^a   Prevoo, W ^a   van Tinteren, H ^a   Verwaal, V ^a  

^a ANTONI VAN LEEUWENHOEK HOSPITAL   (Netherlands)

Author keywords

Colorectal cancer; Neoadjuvant chemotherapy; Peritoneal carcinomatosis; Response; Unresectable

Indexed keywords

ANTINEOPLASTIC AGENT; BEVACIZUMAB; CAPECITABINE; FLUOROURACIL; OXALIPLATIN; CARCINOEMBRYONIC ANTIGEN; DEOXYCYTIDINE; MONOCLONAL ANTIBODY; PLATINUM COMPLEX;

ADJUVANT CHEMOTHERAPY; ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CARCINOMATOUS PERITONITIS; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CLINICAL PROTOCOL; COLORECTAL CANCER; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; LAPAROSCOPY; LAPAROTOMY; LIVER METASTASIS; MALE; MULTIMODALITY CANCER THERAPY; MULTIPLE CYCLE TREATMENT; OBSERVATIONAL STUDY; PERITONEAL BIOPSY; PILOT STUDY; PREOPERATIVE CARE; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; PROSPECTIVE STUDY; SMALL INTESTINE PERFORATION; TREATMENT RESPONSE; TUMOR VOLUME; ADJUVANT THERAPY; ANALOGS AND DERIVATIVES; BLOOD; CARCINOMA; COLORECTAL TUMOR; DISEASE COURSE; DRUG ADMINISTRATION; MIDDLE AGED; PATHOLOGY; PERITONEAL NEOPLASMS; PROCEDURES; PROGNOSIS; SECONDARY; TREATMENT OUTCOME;

ADULT; AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOEMBRYONIC ANTIGEN; CARCINOMA; COLORECTAL NEOPLASMS; DEOXYCYTIDINE; DISEASE PROGRESSION; DRUG ADMINISTRATION SCHEDULE; FEMALE; FLUOROURACIL; HUMANS; LAPAROSCOPY; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; ORGANOPLATINUM COMPOUNDS; PERITONEAL NEOPLASMS; PILOT PROJECTS; PROGNOSIS; PROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84904399378     PISSN: 14628910     EISSN: 14631318     Source Type: Journal    
DOI: 10.1111/codi.12560     Document Type: Article

References (30)

1. Jayne D, Fook S, Seow-Choen F. Peritoneal carcinomatosis from colorectal cancer. Br J Surg 2002; 89: 1545-50.
2. Folprecht G, Köhne C, Lutz M. Systemic chemotherapy in patients with peritoneal carcinomatosis from colorectal cancer. Cancer Treat Res 2007; 134: 425-40.
3. Hompes D, Tiek J, D'Hoore A. HIPEC in T4a colon cancer: a defendable treatment to improve oncologic outcome? Ann Oncol 2012; 23: 3123-9.
4. Chu D, Lang N, Thompson C. Peritoneal carcinomatosis in nongynecologic malignancy. A prospective study of prognostic factors. Cancer 1989; 63: 364-7.
5. Sadeghi B, Arvieux C, Gilly F. Peritoneal carcinomatosis from non-gynecologic malignancies. Results of the EVOCAPE I multicentric prospective study. Cancer 2000; 88: 358-63.
6. Elias D, Gilly F, Glehen O. Peritoneal carcinomatosis treated with surgery and perioperative intraperitoneal chemotherapy: retrospective analysis of 523 patients from a multicentric French study. J Clin Oncol 2010; 28: 63-8.
7. Davies J, O'Neil B. Peritoneal carcinomatosis of gastrointestinal origin: natural history and treatment options. Expert Opin Investig Drugs 2009; 18: 913-9.
8. Bloemendaal AL, Verwaal VJ, van Ruth S. Conventional surgery and systemic chemotherapy for peritoneal carcinomatosis of colorectal origin: a prospective study. Eur J Surg Oncol 2005; 31: 1145-51.
9. Hompes D, Boot H, van Tinteren H, Verwaal V. Unresectable peritoneal carcinomatosis from colorectal cancer: a single center experience. J Surg Oncol 2011; 104: 269-73.
10. Elias D, Lefevre J, Chevalier J. Complete cytoreductive surgery plus intraperitoneal chemohyperthermia with oxaliplatin for peritoneal carcinomatosis of colorectal origin. J Clin Oncol 2009; 27: 681-5.
11. Cao C, Yan T, Morris D. A systematic review and meta-analysis of cytoreductive surgery with perioperative intraperitoneal chemotherapy for peritoneal carcinomatosis of colorectal origin. Ann Surg Oncol 2009; 16: 2152-65.
12. De Gramont A, Figer A, Seymour M. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2000; 18: 2938-47.
13. Koppe M, Boerman O, Oyen W. Peritoneal carcinomatosis of colorectal origin: incidence and strategies. Ann Surg 2006; 243: 212-22.
14. Verwaal V, van Ruth S, de Bree E. Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer. J Clin Oncol 2003; 21: 3737-43.
15. Pelz J, Chua T, Esquivel J. Evaluation of best supportive care and systemic chemotherapy as treatment stratified according to the retrospective Peritoneal Surface Disease Severity Score (PSDSS) for peritoneal carcinomatosis of colorectal origin. BMC Cancer 2010; 10: 689.
16. Köhne C, Vanhoefer U, Hartung G. Clinical predictive factors. Eur J Cancer 2009; 45: 43-9.
17. Swellengrebel H, Zoetmulder F, Verwaal V. Quantitative intra-operative assessment of peritoneal carcinomatosis - a comparison of three prognostic tools. Eur J Surg Oncol 2009; 35: 1078-84.
18. Verwaal V, van Tinteren H, van Ruth S. Predicting the survival of patients with peritoneal carcinomatosis of colorectal origin treated by aggressive cytoreduction and hyperthermic intraperitoneal chemotherapy. Br J Surg 2004; 91: 739-46.
19. A'Hern RP. Sample size tables for exact single stage phase II designs. Stat Med 2001; 20: 859-66.
20. Oken M, Creech R, Tormey D. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982; 5: 649-55.
21. Adam R, Vibert E, Pitombo M. Induction chemotherapy and surgery for colorectal liver metastases. Bull Cancer 2006; 93(Suppl. 1): S45-9.
22. Alberts S, Poston G. Treatment advances in liver-limited metastatic colorectal cancer. Clin Colorectal Cancer 2011; 10: 258-65.
23. Bismuth H, Adam R, Levi F. Resection of nonresectable liver metastases from colorectal cancer after neoadjuvant chemotherapy. Ann Surg 1996; 224: 509-20.
24. Adam R, Delvart V, Pascal G. Rescue surgery for unresectable colorectal liver metastases downstaged by chemotherapy: a model to predict long-term survival. Ann Surg 2004; 240: 644-57.
25. Van Cutsem E, Nordlinger B, Adam R. Towards a pan-European consensus on the treatment of patients with colorectal liver metastases. Eur J Cancer 2006; 42: 2212-21.
26. Passot G, Vaudoyer D, Cotte E. Progression following neoadjuvant systemic chemotherapy may not be a contradiction to a curative approach for colorectal carcinomatosis. Ann Surg 2012; 256: 125-9.
27. Klaver Y, Leenders B, Creemers G. Addition of biological therapies to palliative chemotherapy prolongs survival in patients with peritoneal carcinomatosis of colorectal origin. Am J Clin Oncol 2013; 36: 157-61.
28. Zani S, Papalezova K, Stinnett S. Modest advances in survival for patients with colorectal-associated peritoneal carcinomatosis in the era of modern chemotherapy. J Surg Oncol 2013; 107: 307-11.
29. Stillwell A, Ho Y, Veitch C. Systemic review of prognostic factors related to overall survival in patients with stage IV colorectal cancer and unresectable metastases. World J Surg 2011; 35: 684-92.
30. Pelz J, Stojadinovic A, Nissan A. Evaluation of peritoneal disease severity score in patients with colon cancer with peritoneal carcinomatosis. J Surg Oncol 2009; 99: 9-15.